This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. http://www.researchmoz.us/relapsed-multiple-myeloma-pipeline-review-h1-2015-report.html

1. Relapsed Multiple Myeloma - Pipeline Review, H1 2015
Global Markets Direct’s, ‘Relapsed Multiple Myeloma Pipeline Review, H1 2015’, provides an overview of the Relapsed Multiple
Myeloma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various
stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and
featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on
late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is
built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s
team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated
with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking
ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
The report provides a snapshot of the global therapeutic landscape of Relapsed Multiple Myeloma The report reviews key pipeline products under drug profile
section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key
players involved in the therapeutics development for Relapsed Multiple Myeloma and enlists all their major and minor projects The report summarizes all the
dormant and discontinued pipeline projects A review of the Relapsed Multiple Myeloma products under development by companies and universities/research
institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging
from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the
Relapsed Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline
products Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players
with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the
focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Relapsed Multiple Myeloma Plan
mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding
Relapsed Multiple Myeloma pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying
discontinued projects and understanding the factors that drove them from pipeline
table Of Contents
table Of Contents 2
list Of Tables 6
list Of Figures 8
introduction 9
global Markets Direct Report Coverage 9
relapsed Multiple Myeloma Overview 10
therapeutics Development 11
pipeline Products For Relapsed Multiple Myeloma - Overview 11
pipeline Products For Relapsed Multiple Myeloma - Comparative Analysis 12
relapsed Multiple Myeloma - Therapeutics Under Development By Companies 13
relapsed Multiple Myeloma - Therapeutics Under Investigation By Universities/institutes 17
relapsed Multiple Myeloma - Pipeline Products Glance 18
late Stage Products 18
clinical Stage Products 19
relapsed Multiple Myeloma - Products Under Development By Companies 20
relapsed Multiple Myeloma - Products Under Investigation By Universities/institutes 25
relapsed Multiple Myeloma - Companies Involved In Therapeutics Development 26
4sc Ag 26
ab Science 27
abbvie Inc. 28
acceleron Pharma, Inc. 29
acetylon Pharmaceuticals, Inc. 30
altor Bioscience Corporation 31
arno Therapeutics, Inc. 32
array Biopharma Inc. 33
astellas Pharma Inc. 34
astex Pharmaceuticals, Inc. 35
Relapsed Multiple Myeloma - Pipeline Review, H1 2015

2. biotest Ag 36
bristol-myers Squibb Company 37
celgene Corporation 38
cellectar Biosciences, Inc. 39
chroma Therapeutics Ltd. 40
curetech Ltd. 41
curis, Inc. 42
exelixis, Inc. 43
f. Hoffmann-la Roche Ltd. 44
glaxosmithkline Plc 45
immunomedics, Inc. 46
johnson & Johnson 47
karyopharm Therapeutics, Inc. 48
medimmune, Llc 49
merck & Co., Inc. 50
millennium Pharmaceuticals, Inc. 51
morphosys Ag 52
novartis Ag 53
noxxon Pharma Ag 54
oncolytics Biotech Inc. 55
oncopeptides Ab 56
onyx Pharmaceuticals, Inc. 57
patrys Limited 58
pfizer Inc. 59
pharma Mar, S.a. 60
pharmacyclics, Inc. 61
prolexys Pharmaceuticals, Inc. 62
sanofi 63
sevion Therapeutics, Inc. 64
stemline Therapeutics, Inc. 65
sumitomo Dainippon Pharma Co., Ltd. 66
synta Pharmaceuticals Corp. 67
threshold Pharmaceuticals, Inc. 68
vivolux Ab 69
relapsed Multiple Myeloma - Therapeutics Assessment 70
assessment By Monotherapy Products 70
assessment By Combination Products 71
assessment By Target 72
assessment By Mechanism Of Action 77
assessment By Route Of Administration 81
assessment By Molecule Type 83
drug Profiles 85
4sc-202 - Drug Profile 85
acp-196 - Drug Profile 87
afuresertib Hydrochloride - Drug Profile 89
alisertib - Drug Profile 91
alpelisib - Drug Profile 95
alt-801 - Drug Profile 97
alt-803 - Drug Profile 99
amrubicin Hydrochloride - Drug Profile 101
ar-42 - Drug Profile 103
at-7519 - Drug Profile 105
at-9283 - Drug Profile 108
b-701 - Drug Profile 110
bendamustine Hydrochloride - Drug Profile 111
cabozantinib S-malate - Drug Profile 114
carfilzomib - Drug Profile 117
cb-5083 - Drug Profile 121
cc-90002 - Drug Profile 122
cell Therapy To Target Cd138 For Relapsed And Refractory Multiple Myeloma - Drug Profile 123
chr-3996 - Drug Profile 124
cudc-907 - Drug Profile 125
dalantercept - Drug Profile 127
daratumumab - Drug Profile 129
dasatinib - Drug Profile 132
dkn-01 - Drug Profile 135
elotuzumab - Drug Profile 137
erismodegib - Drug Profile 139
Relapsed Multiple Myeloma - Pipeline Review, H1 2015

3. evofosfamide - Drug Profile 142
filanesib - Drug Profile 149
ganetespib - Drug Profile 151
gsk-2857916 - Drug Profile 156
gsk-525762 - Drug Profile 157
i131-clr1404 - Drug Profile 158
ibrutinib - Drug Profile 160
indatuximab Ravtansine - Drug Profile 166
isatuximab - Drug Profile 168
ixazomib Citrate - Drug Profile 170
lcl-161 - Drug Profile 173
lgh-447 - Drug Profile 175
linsitinib - Drug Profile 176
marizomib - Drug Profile 178
masitinib - Drug Profile 180
medi-551 - Drug Profile 183
melflufen - Drug Profile 185
milatuzumab - Drug Profile 187
mln-0128 - Drug Profile 189
mor-202 - Drug Profile 191
mv-nis - Drug Profile 193
olaptesed Pegol - Drug Profile 195
oprozomib - Drug Profile 198
palbociclib - Drug Profile 200
panobinostat - Drug Profile 204
patsm-6 - Drug Profile 210
pelareorep - Drug Profile 212
pembrolizumab - Drug Profile 217
pidilizumab - Drug Profile 223
plerixafor - Drug Profile 225
plitidepsin - Drug Profile 227
pomalidomide - Drug Profile 229
prlx-93936 - Drug Profile 233
quisinostat - Drug Profile 235
recombinant Protein For Oncology - Drug Profile 237
ricolinostat - Drug Profile 239
selinexor - Drug Profile 241
sl-401 - Drug Profile 245
sns-01t - Drug Profile 247
trametinib Dimethyl Sulfoxide + Uprosertib - Drug Profile 248
ulocuplumab - Drug Profile 250
urelumab - Drug Profile 252
vemurafenib - Drug Profile 254
venetoclax - Drug Profile 258
vlx-1570 - Drug Profile 261
vorinostat - Drug Profile 262
relapsed Multiple Myeloma - Recent Pipeline Updates 266
relapsed Multiple Myeloma - Dormant Projects 418
relapsed Multiple Myeloma - Discontinued Products 421
relapsed Multiple Myeloma - Product Development Milestones 422
featured News & Press Releases 422
appendix 432
methodology 432
coverage 432
secondary Research 432
primary Research 432
expert Panel Validation 432
contact Us 432
disclaimer 433
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
Relapsed Multiple Myeloma - Pipeline Review, H1 2015

4. Sales Team,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Relapsed Multiple Myeloma - Pipeline Review, H1 2015